Abstract:BACKGROUND: There is a growing recognition that the adipose tissue is an endocrine organ that secretes signaling molecules such as adiponectin and resistin. The peroxisome proliferator activated receptor γ (PPARγ) is expressed in high levels in the adipose tissue. Thiazolidinediones are selective PPARγ agonists with insulin-sensitizing properties. It has been postulated that thiazolidinediones such as rosiglitazone exert their pharmacodynamic effects in part through modulation of resistin (implicated in insulin resistance) and adiponectin (an insulin-sensitizing molecule) expression subsequent to activation of PPARγ. There are conflicting data, however, on the biological direction in which resistin expression is modulated by PPARγ agonists and whether an increase in adiponectin expression can occur in the face of an upregulation of resistin. METHODS: Using the murine 3T3-L1 adipocytes as a model, we evaluated the changes in resistin and adiponectin gene expression after vehicle, rosiglitazone (10 μmol/L, a PPARγ agonist), GW9662 (5 μmol/L, a selective PPARγ antagonist) or GW662 and rosiglitazone co-treatment.RESULTS: In comparison to vehicle treatment, rosiglitazone increased the average adiponectin and resistin mRNA expression by 1.66- and 1.55-fold, respectively (P＜0.05). Importantly, GW9662 also upregulated adiponectin expression (by 1.57-fold, P＜0.05) but did not influence resistin expression (P＞0.05). Co-treatment with rosiglitazone and GW9662 maintained the adiponectin upregulation (1.87-fold increase from vehicle, P＜0.05) while attenuating resistin upregulation (1.31-fold increase from vehicle, P＜0.05) induced by rosiglitazone alone (1.55-fold increase from vehicle, P＜0.05). CONCLUSION: This study presents new evidence that adiponectin transcript is upregulated with both a PPARγ agonist (rosiglitazone) and antagonist (GW9662), while GW9662 co-treatment does not block rosiglitazone-induced adiponectin upregulation. These data collectively suggest that biological mechanisms independent from PPARγ may underlie thiazolidinedione pharmacodynamics on adiponectin expression. Moreover, increased adiponectin expression by GW9662, in the absence of an upregulation of resistin expression, lends further support on the emerging clinical potential of PPARγ antagonists in treatment of insulin resistance. Decreased resistin expression may not be crucial for the insulin-sensitizing effect of rosiglitazone. These findings may serve as a foundation for future dose-ranging and time-course studies of thiazolidinedione pharmacodynamics on adipocytokine expression in human adipocytes.

Adiponectin-impaired Adipocyte Differentiation Negatively Regulates Fat Deposition in Chicken.

Adiponectin Decreases Lipids Deposition by P38 MAPK/ATF2 Signaling Pathway in Muscle of Broilers

Adiponectin Impairs Chicken Preadipocytes Differentiation Through P38 MAPK/ATF-2 and TOR/p70 S6 Kinase Pathways

Recombinant Globular Adiponectin Inhibits Lipid Deposition by P38 MAPK/ATF-2 and TOR/p70 S6 Kinase Pathways in Chicken Adipocytes.

Adiponectin Prevents Reduction of Lipid-Induced Mitochondrial Biogenesis Via Ampk/Acc2 Pathway in Chicken Adipocyte

Adiponectin Reduces Lipid Content in Chicken Myoblasts by Activating AMPK Signaling Pathway

Adiponectin/adiponectin Receptors Mrna Expression Profiles in Chickens and Their Response to Feed Restriction

Synergistic Effect of Genistein and Adiponectin Reduces Fat Deposition in Chicken Hepatocytes by Activating the ERβ-mediated SIRT1-AMPK Signaling Pathway

Chicken Adipocyte Fatty Acid-Binding Protein Knockdown Affects Expression of Peroxisome Proliferator-Activated Receptor Γ Gene During Oleate-Induced Adipocyte Differentiation.

The Adiponectin Receptor Agonist, AdipoRon, Promotes Reproductive Hormone Secretion and Gonadal Development Via the Hypothalamic-Pituitary-gonadal Axis in Chickens.

Effects of Rosiglitazone on Adiponectin Expression in Cultured Adipocytes of Obese Patients

Adiponectin/adiponectin receptors mRNA expression profiles in chickens and their response to feed restriction.

Adiponectin Inhibits GnRH Secretion Via Activating AMPK and PI3K Signaling Pathways in Chicken Hypothalamic Neuron Cells.

Effects of Rosiglitazone on Adiponectin Expression in 3T3-L1 Adipocytes at High Levels of Both Testosterone and Insulin in Vitro Culture

Adiponectin modulates steroid hormone secretion, granulosa cell proliferation and apoptosis via binding its receptors during hens’ high laying period

The role of AdipoQ on proliferation, apoptosis, and hormone Secretion in chicken primary adenohypophysis cells

Genistein Activated Adenosine 5′-Monophosphate-activated Protein Kinase–sirtuin1/peroxisome Proliferator-Activated Receptor Γ Coactivator-1Α Pathway Potentially Through Adiponectin and Estrogen Receptor Β Signaling to Suppress Fat Deposition in Broiler Chickens

Adipose tissue fat accumulation is reduced by a single intraperitoneal injection of peroxisome proliferator-activated receptor gamma agonist when given to newly hatched chicks.

Growth hormone receptor gene influences mitochondrial function and chicken lipid metabolism by AMPK-PGC1α-PPAR signaling pathway

Differential effects of PPARγ ligand rosiglitazone and selective antagonist GW9662 on adipocytokine gene expression in 3T3-L1 adipocytes

Gene Expression of Adiponectin and Adiponectin Receptor 1 in Type 2 Diabetic Rats and the Relationship with the Parameters of Glucose and Lipid Metabolism